News Report · Oncology

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

June 13, 2026

Clinical Perspective

Imlunestrant is indicated for adults with ESR1-mutated, HR-positive, HER2-negative advanced breast cancer who have experienced disease progression after at least one line of endocrine therapy. The data supports a median PFS improvement of 5.5 months compared to standard endocrine therapies. What additional benefits might imlunestrant provide in combination with other treatments?

Dr. Meera Pillai · Oncology

Imlunestrant (Inluriyo) reduced progression-free survival (PFS) by 5.5 months versus investigator's choice of endocrine therapy in patients with ESR1-mutated, HR-positive, HER2-negative advanced breast cancer ^[1].

Clinical Context

Breast cancer is a leading cause of cancer-related morbidity and mortality worldwide, with an estimated 2.3 million new cases diagnosed in 2022 ^[2]. Hormone receptor-positive (HR+) and HER2-negative breast cancer represents a significant subset of this disease, often treated with endocrine therapies. However, resistance to these therapies can occur, particularly in patients with ESR1 mutations, leading to disease progression. The introduction of targeted therapies, such as CDK4/6 inhibitors and now imlunestrant, aims to address this resistance and improve outcomes in this patient population. This approval of imlunestrant provides a new treatment option for patients who have progressed on prior endocrine therapies.

Key Findings

The EMBER-3 trial showed imlunestrant achieved a median PFS of 5.5 months versus 3.8 months with investigator's choice of endocrine therapy (HR 0.62; 95% CI 0.46-0.82) ^[1].
The trial enrolled 874 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with an aromatase inhibitor ^[1].
Event rates: 14.3% objective response rate (ORR) in the imlunestrant arm versus 7.7% in the investigator's choice arm ^[1].
The primary endpoint was investigator-assessed progression-free survival (PFS) ^[1].
Secondary outcome measures included overall survival (OS) and objective response rate (ORR) ^[1].
Imlunestrant is administered at a dose of 400 mg orally once daily ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Fatigue reported with imlunestrant — exact frequency not available in public source summary ^[1].
Nausea reported — exact frequency not available in public source summary ^[1].
Musculoskeletal pain reported ^[1].
Decreased hemoglobin reported ^[1].
Increased AST reported ^[1].
Complete adverse event profile available in the full prescribing information for imlunestrant (Inluriyo) ^[1].

Study Design

The EMBER-3 trial was a randomized, open-label, active-controlled, multicenter study that enrolled 874 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. The primary endpoint was investigator-assessed progression-free survival (PFS), with a follow-up duration sufficient to assess the primary and secondary endpoints. The trial was funded by Eli Lilly and Company, and key limitations include the need for further data on overall survival and long-term safety outcomes.

FAQ

What is imlunestrant approved for?

Imlunestrant (Inluriyo) is approved for adults with ESR1-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

How does imlunestrant work?

Imlunestrant is an estrogen receptor antagonist that targets the estrogen receptor to inhibit tumor growth in HR-positive breast cancer.

What is the recommended dose of imlunestrant?

The recommended dose of imlunestrant is 400 mg orally once daily, taken on an empty stomach at least 2 hours before food or 1 hour after food. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of imlunestrant?

Common side effects include fatigue, nausea, musculoskeletal pain, decreased hemoglobin, and increased liver enzymes (AST).

How does imlunestrant compare to other treatments?

Imlunestrant has shown a median PFS improvement of 5.5 months compared to investigator's choice of endocrine therapy in patients with ESR1 mutations.

Who qualifies for imlunestrant treatment?

Patients with ESR1-mutated, HR-positive, HER2-negative advanced breast cancer who have progressed after at least one line of endocrine therapy qualify for treatment with imlunestrant.

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

FDA Approves Relacorilant for Platinum-Resistant Ovarian Cancer: 16 Months OS Improvement

FDA Approves Mirdametinib for Neurofibromatosis Type 1: 41% ORR in ReNeu Trial

Verified HCP Portal